Cancer drug dasatinib shows promise in early HIV control trial
Disease control
Ongoing
This study tests whether dasatinib, a drug currently used for leukemia, can safely control HIV in people who were infected within the past 3 to 12 months and have not yet taken standard HIV medications. Participants receive either dasatinib or a placebo for 16 weeks. The goal is …
Phase: PHASE2 • Sponsor: Eva Bonfill • Aim: Disease control
Last updated Jul 08, 2026 00:00 UTC